Novartis, The Max Foundation, and a young girl who dreamed to be a lawyer
The Max Foundation and Novartis renew their commitment to CML patients
The Max Foundation and partner NGO Esperantra are pleased to announce they have signed a new MOU that will help patients in Peru gain access to treatment.
Esperantra, a non-profit organization working to reduce cancer mortality in Peru, has generously agreed to partner with The Max Foundation to facilitate the importation of medicines within Max Access Solutions.
“Esperantra and The Max Foundation are a perfect fit together,” said Inés García González, The Max Foundation’s Region Head for Latin America. “Our organizations have similar goals – expanding access to treatment, reducing cancer mortality, etc. – and Esperantra is a well-established organization in Peru with a great track record. We are honored to partner with them.”
Karla Ruiz de Castilla, Esperantra’s Executive Director, said: “It is our pleasure to partner with The Max Foundation and help expand access to treatment for patients in Peru. Together we are improving clinical outcomes and quality of life for people facing cancer.”
Thanks to the partnership with Esperantra, Peru has become the 70th country to have patients enrolled in Max Access Solutions.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
In 2017 The Max Foundation, through its subsidiary MaxAid, and Novartis have renewed their commitment to patients by launching CMLPath to Care™ a new collaboration aimed at providing humanitarian access to treatment for CML and other rare cancers for those patients for whom no other form of local treatment access exists today. CMLPath to Care consists of humanitarian product donations and funding support from Novartis to Max, and an innovative new distribution model developed and implemented by Max and its international distributor, under the Max Access Solution umbrella.
Agreement to provide Verzenio® (abemaciclib) free of charge to patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) Lilly joins ongoing effort of Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) to eliminate healthcare disparities for patients living with advanced breast cancer in low- and middle-income countries….